Additional file 5 of Organization of self-advantageous niche by neural stem/progenitor cells during development via autocrine VEGF-A under hypoxia by Taichi Kashiwagi (2430256)

“…NeuN+ neurons were significantly decreased by the hypoxic condition (Mean ± SEM, n = 4, *** p = 0.00028. …”

Dexamethasone treatment modifies <i>PTGDR</i> promoter activity. by Elena Marcos-Vadillo (4557103)

Set1 complex Set1 and Swd1 subunits associate in meiosis with highly transcribed genes, but not with chromosome axis sites. by Céline Adam (320770)

Nonequilibrium Arrhythmic States and Transitions in a Mathematical Model for Diffuse Fibrosis in Human Cardiac Tissue by Rupamanjari Majumder (128411)

“…Our study of a single myocyte-fibroblast (MF) composite, with a single myocyte coupled to fibroblasts via a gap-junctional conductance , reveals five qualitatively different responses for this composite. …”

Artificial data: influence of the nature and amount of inter-subject variability on the mean accuracy (± standard error). by Sylvain Takerkart (5659873)

Relationships between each parameter relative change and stent wire mesh density. by Shunsuke Masuda (12859231)

Assessment of the membrane NMDA and AMPA receptor expression after optogenetic stimulation of hippocampal CA1 astrocytes. by Jae-Hong Kim (124622)

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Platelets were inhibited by PFC administration and activated in response to LPS. by Heather F. Pidcoke (9023789)

Fig 2 - by Karolina Pawlak (13813008)

Sequence alignments of HBV from high-throughput bisulfite sequencing or different HBV genotypes. by Jiangpeng Feng (9287738)

OPTN does not affect cell proliferation. by Xiao Chen Shi (8611887)

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study by George Zarkavelis (10817434)

“…The ORR in the per protocol population (PP) was 42.9%. Within a median follow-up of 56 months, the median PFS and OS in the ITT population was 5.0 and 8.7 months, respectively. …”

Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

Image 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

“…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”

NADPH-linked reductase activity assay of recombinant MsrA and MsrB from <i>S.</i> Typhimurium. by Luisa A. Denkel (199456)

“…<p><b>A.</b> The graph shows the amount of oxidized NADPH per minute for the reduction of 500, 100, 50 and 5 µM methyl <i>p</i>-tolyl sulfoxide by MsrA and MsrB, respectively. …”

Changes in the fish community at Molokini. by Kevin C. Weng (8554347)